Literature DB >> 12644763

Topical mitomycin treatment for primary acquired melanosis of the conjunctiva.

Vernon Ho Yuen1, David R Jordan, Seymour Brownstein, Michael W Dorey.   

Abstract

A case of primary acquired melanosis of the conjunctiva primarily treated with topical mitomycin chemotherapy is presented. The patient underwent treatment with one 2-week course of topical mitomycin 0.02% four times daily, followed 4 weeks later by a 2-week course of topical mitomycin 0.04% four times daily, followed by a 3-month course of topical mitomycin 0.02% twice daily. Map biopsies were performed after the initial two courses of mitomycin therapy and 12 months after all courses of mitomycin treatment had been completed. Complete resolution of the conjunctival pigmentation was noted after the final course of treatment. Map biopsies performed at 12 months following completion of treatment showed normal conjunctiva histopathologically. No recurrence of pigmentation was noted in follow-up 26 months after completion of treatment. Topical mitomycin chemotherapy may be a successful primary treatment for primary acquired melanosis of the conjunctiva.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12644763     DOI: 10.1097/01.IOP.0000055826.30486.CC

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  5 in total

1.  Primary acquired melanosis of the conjunctiva: experience with 311 eyes.

Authors:  Jerry A Shields; Carol L Shields; Arman Mashayekhi; Brian P Marr; Raquel Benavides; Archana Thangappan; Laura Phan; Ralph C Eagle
Journal:  Trans Am Ophthalmol Soc       Date:  2007

2.  Efficacy of low-dose topical mitomycin C treatment for primary acquired melanosis.

Authors:  Susan Hung; Tony Tsai; David Hwang; Joan O'Brien
Journal:  BMJ Case Rep       Date:  2009-06-01

3.  Topical treatment options for conjunctival neoplasms.

Authors:  Jonathan W Kim; David H Abramson
Journal:  Clin Ophthalmol       Date:  2008-09

Review 4.  [Topical Mitomycin C as a therapy of conjunctival tumours].

Authors:  M Schallenberg; N Niederdräing; K-P Steuhl; D Meller
Journal:  Ophthalmologe       Date:  2008-08       Impact factor: 1.059

Review 5.  [Adjuvant therapy and interdisciplinary follow-up care of conjunctival melanoma].

Authors:  L M Heindl; K R Koch; M Schlaak; C Mauch; C Cursiefen
Journal:  Ophthalmologe       Date:  2015-11       Impact factor: 1.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.